Preparing for the next pandemic.

The fragile and limited production capacity of our 1950s egg-based technology for producing influenza vaccine and the lack of a national commitment to universal annual influenza vaccination mean that influenza epidemics will continue to present a substantial public health challenge. Dr. Michael Osterholm asks, So how can we prepare?

[1]  J. Teale,et al.  Initial Delay in the Immune Response to Francisella tularensis Is Followed by Hypercytokinemia Characteristic of Severe Sepsis and Correlating with Upregulation and Release of Damage-Associated Molecular Patterns , 2008, Infection and Immunity.

[2]  A. Nath,et al.  Burden of neuroinfectious diseases on the neurology service in a tertiary care center , 2008, Neurology.

[3]  D. Talmor,et al.  Definitive Care for the Critically Ill During a Disaster: Medical Resources for Surge Capacity , 2008, Chest.

[4]  T. Cook,et al.  Development of a triage protocol for critical care during an influenza pandemic , 2006, Canadian Medical Association Journal.

[5]  J. Peiris,et al.  Re-emergence of fatal human influenza A subtype H5N1 disease , 2004, The Lancet.

[6]  K. Stöhr.  Avian influenza and pandemics--research needs and opportunities. , 2005, The New England journal of medicine.

[7]  H. Guzmán,et al.  Dhori virus (Orthomyxoviridae: Thogotovirus) infection of mice produces a disease and cytokine response pattern similar to that of highly virulent influenza A (H5N1) virus infection in humans. , 2008, The American journal of tropical medicine and hygiene.

[8]  A. Pollard,et al.  Physicians’ perception of pandemic influenza , 2007, Archives of Disease in Childhood.

[9]  Niall Johnson,et al.  Updating the Accounts: Global Mortality of the 1918-1920 "Spanish" Influenza Pandemic , 2002, Bulletin of the history of medicine.

[10]  G. Freund,et al.  Augmented Lipopolysaccharide-Induced TNF-α Production by Peritoneal Macrophages in Type 2 Diabetic Mice Is Dependent on Elevated Glucose and Requires p38 MAPK1 , 2007, The Journal of Immunology.

[11]  J. Bartlett,et al.  Influenza A (H5N1): Will It Be the Next Pandemic Influenza? Are We Ready? , 2005, Annals of Internal Medicine.

[12]  E. Baker,et al.  Will the Chickens come Home to Roost? , 1970, Nature.

[13]  E Ray Dorsey,et al.  Financial anatomy of biomedical research. , 2005, JAMA.

[14]  R. Davey,et al.  Pharmacokinetics and Tolerability of Oseltamivir Combined with Probenecid , 2008, Antimicrobial Agents and Chemotherapy.

[15]  Punam Mangtani,et al.  Estimates of the reproduction numbers of Spanish influenza using morbidity data. , 2007, International journal of epidemiology.

[16]  J. Geiling,et al.  Definitive Care for the Critically Ill During a Disaster: Current Capabilities and Limitations , 2008, Chest.

[17]  Jennifer Thomas,et al.  Avian influenza: a review. , 2007, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.

[18]  M. Carter.  A rationale for using steroids in the treatment of severe cases of H5N1 avian influenza. , 2007, Journal of medical microbiology.

[19]  Hidekazu Nishimura,et al.  Enhanced virulence of influenza A viruses with the haemagglutinin of the 1918 pandemic virus , 2004, Nature.